Guccini et al. show that TIMP1 loss switches senescence from a tumor-suppressive to a pro-metastatic process in prostate cancer mouse models. Pharmacological targeting of TIMP1-deficient senescent tumor cells impedes metastases in mice, thereby validating the therapeutic potential of senolytic therapy in prostate cancer.
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Alimonti A.
2021
Abstract
Guccini et al. show that TIMP1 loss switches senescence from a tumor-suppressive to a pro-metastatic process in prostate cancer mouse models. Pharmacological targeting of TIMP1-deficient senescent tumor cells impedes metastases in mice, thereby validating the therapeutic potential of senolytic therapy in prostate cancer.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
